Recent Content
- Dr Ignatz-Hoover on Bispecific Antibodies in the Multiple Myeloma Treatment Armamentarium
- Erratum for the Research Article “Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma” by S. Manier et al
- Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews
- Toxicity of CAR T-Cell Therapy for Multiple Myeloma
- Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study
- Improved overall survival of transplant eligible newly diagnosed multiple myeloma patients in a Chilean public center. How did we achieve it?
- Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis
- Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization
- Treatment of multiple myeloma: What is the impact on T-cell function?
- Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group